Skip to main content
Mothaffar Rimawi, MD, Oncology, Houston, TX

MothaffarF.RimawiMD

Oncology Houston, TX

Breast Cancer

Professor and Executive Medical Director, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine

Dr. Rimawi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rimawi's full profile

Already have an account?

  • Office

    1504 Taub Loop
    Houston, TX 77030
    Phone+1 713-873-8890
    Fax+1 713-798-8884

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicinePost-Doctoral Fellowship, 2003 - 2005
  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
  • University of Jordan Faculty of Medicine
    University of Jordan Faculty of MedicineClass of 1997

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2005 - 2026
  • IN State Medical License
    IN State Medical License 2004 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctors:SE Texas Castle Connolly, 2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine Resistance  
    Rinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature

Lectures

  • Advances in HER2-Positive Breast Cancer 
    2012 International Symposium, San Antonio, Texas, USA
  • Advances in HER2-Positive Breast Cancer 
    San Antonio Breast Cancer Symposium, 2012 International Symposium, San Antonio, Texas, USA

Press Mentions

  • Greenwich LifeSciences Provides Year End Update
    Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022
  • NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
    NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast CancerJune 14th, 2022
  • Long-Term Repercussions of Postponing Care Due to COVID-19
    Long-Term Repercussions of Postponing Care Due to COVID-19March 8th, 2021
  • Join now to see all

Professional Memberships

Other Languages

  • Arabic